Calcium, vitamin D and cardiovascular disease

Kidney and Blood Pressure Research

Volumn 34, Issue 6, 2011, Pages 404-417

  Guessous, Idris ^a,b   Bochud, Murielle ^b   Bonny, Olivier ^c   Burnier, Michel ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Calcium; Cardiovascular disease; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; COLECALCIFEROL; VITAMIN D;

BLOOD PRESSURE REGULATION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION;

ANIMALS; BLOOD PRESSURE; CALCIUM; CALCIUM, DIETARY; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D;

EID: 79958773262     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000328332     Document Type: Review

References (140)

1. Allender PS, et al: Dietary calcium and blood pressure: A meta-analysis of randomized clinical trials. Ann Intern Med 1996; 124: 825-831.
2. Bucher HC, et al: Effects of dietary calcium supplementation on blood pressure. A metaanalysis of randomized controlled trials. JAMA 1996; 275: 1016-1022.
3. Cappuccio FP, Siani A, Strazzullo P: Oral calcium supplementation and blood pressure: An overview of randomized controlled trials. J Hypertens 1989; 7: 941-946.
4. Dickinson HO, et al: Calcium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev 2006;CD004639.
5. Griffith LE, et al: The influence of dietary and nondietary calcium supplementation on blood pressure: An updated meta-analysis of randomized controlled trials. Am J Hypertens 1999; 12: 84-92.
6. Van Mierlo LA, et al: Blood pressure response to calcium supplementation: A metaanalysis of randomized controlled trials. J Hum Hypertens 2006; 20: 571-580.
7. Chung M, et al: Vitamin D and calcium: A systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 2009; 183: 1-420.
8. Miller GD, et al: Benefits of dairy product consumption on blood pressure in humans: A summary of the biomedical literature. J Am Coll Nutr 2000; 19(suppl):147S-164S.
9. Alonso A, et al: Low-fat dairy consumption and reduced risk of hypertension: The Seguimiento Universidad de Navarra (SUN) cohort. Am J Clin Nutr 2005; 82: 972-979.
10. Ascherio A, et al: A prospective study of nutritional factors and hypertension among US men. Circulation 1992; 86: 1475-1484.
11. Dwyer JH, et al: Dietary calcium, alcohol, and incidence of treated hypertension in the NHANES I epidemiologic follow-up study. Am J Epidemiol 1996; 144: 828-838.
12. Ford ES, Cooper RS: Risk factors for hypertension in a national cohort study. Hypertension 1991; 18: 598-606.
13. Wang L, et al: Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008; 51: 1073-1079.
14. Ascherio A, et al: Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 1996; 27: 1065-1072.
15. Schatzkin A, et al: A comparison of a food frequency questionnaire with a 24-hour recall for use in an epidemiological cohort study: Results from the biomarker-based Observing Protein and Energy Nutrition (OPEN) study. Int J Epidemiol 2003; 32: 1054-1062.
16. Bulpitt CJ, Hodes C, Everitt MG: The relationship between blood pressure and biochemical risk factors in a general population. Br J Prev Soc Med 1976; 30: 158-162.
17. Vargas CM, Obisesan T, Gillum RF: Association of serum albumin concentration, serum ionized calcium concentration, and blood pressure in the Third National Health and Nutrition Examination Survey. J Clin Epidemiol 1998; 51: 739-746.
18. Fogh-Andersen N, et al: Sex-dependent relation between ionized calcium in serum and blood pressure. Clin Chem 1984; 30: 116-118.
19. Buckley BM, et al: Lack of evidence of low ionized calcium levels in systemic hypertension. Am J Cardiol 1987; 59: 878-880.
20. Jorde R, et al: Serum calcium and cardiovascular risk factors and diseases: The Tromsø study. Hypertension 1999; 34: 484-490.
21. Lind L, et al: Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease. BMJ 1988; 297: 960-963.
22. Phillips AN, Shaper AG: Serum calcium and blood pressure. J Hum Hypertens 1991; 5: 479-484.
23. Ogard CG, et al: Serum ionised calcium and cardiovascular disease in 45-year-old men and women followed for 18 years. Eur J Epidemiol 2006; 21: 123-127.
24. Jorde R, Bonaa KH, Sundsfjord J: Population- based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol 1999; 141: 350-357.
25. Kesteloot H, Joossens JV: Relationship of serum sodium, potassium, calcium, and phosphorus with blood pressure. Belgian Interuniversity Research on Nutrition and Health. Hypertension 1988; 12: 589-593.
26. Hunt SC, Williams RR, Kuida H: Different plasma ionized calcium correlations with blood pressure in high and low renin normotensive adults in Utah. Am J Hypertens 1991; 4: 1-8.
27. McCarron DA: Low serum concentrations of ionized calcium in patients with hypertension. N Engl J Med 1982; 307: 226-228.
28. Resnick LM: The role of dietary calcium in hypertension: A hierarchical overview. Am J Hypertens 1999; 12: 99-112.
29. Zemel MB: Calcium modulation of hypertension and obesity: Mechanisms and implications. J Am Coll Nutr 2001; 20(suppl):428S- 435S, 440S-442S.
30. Zemel MB: Nutritional and endocrine modulation of intracellular calcium: Implications in obesity, insulin resistance and hypertension. Mol Cell Biochem 1998; 188: 129-136.
31. Bohr DF: Vascular smooth muscle: Dual effect of calcium. Science 1963; 139: 597-599.
32. Ledoux J, et al: Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 2006; 21: 69-78.
33. Iwamoto T, et al: Salt-sensitive hypertension is triggered by Ca 2+ entry via Na+/Ca 2+ exchanger type-1 in vascular smooth muscle. Nat Med 2004; 10: 1193-1199.
34. Zulian A, et al: Up-regulation of Na + /Ca 2+ exchanger and TRPC6 contributes to abnormal Ca 2+ homeostasis in arterial smooth muscle cells from Milan hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 299:H624-H633.
35. Levy D, et al: Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41: 677-687.
36. Resnick LM, et al: Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983; 309: 888-891.
37. Touyz RM, Panz V, Milne FJ: Relations between magnesium, calcium, and plasma renin activity in black and white hypertensive patients. Miner Electrolyte Metab 1995; 21: 417-422.
38. Maillard MP, et al: Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. J Hypertens 2009; 27: 1980-1987.
39. Bolland MJ, et al: Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial. BMJ 2008; 336: 262-266.
40. Grant AM, et al: Oral vitamin D 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet 2005; 365: 1621-1628.
41. Hsia J, et al: Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
42. Prince RL, et al: Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166: 869-875.
43. Bolland MJ, et al: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 2010; 341:c3691.
44. Al-Delaimy WK, et al: A prospective study of calcium intake from diet and supplements and risk of ischemic heart disease among men. Am J Clin Nutr 2003; 77: 814-818.
45. Bostick RM, et al: Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999; 149: 151-161.
46. Marniemi J, et al: Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis 2005; 15: 188-197.
47. Umesawa M, et al: Dietary intake of calcium in relation to mortality from cardiovascular disease: The JACC Study. Stroke 2006; 37: 20-26.
48. Umesawa M, et al: Dietary calcium intake and risks of stroke, its subtypes, and coronary heart disease in Japanese: The JPHC Study Cohort I. Stroke 2008; 39: 2449-2456.
49. Van der Vijver LP, et al: Calcium intake and 28-year cardiovascular and coronary heart disease mortality in Dutch civil servants. Int J Epidemiol 1992; 21: 36-39.
50. Palmer M, et al: Survival and renal function in untreated hypercalcemia: Populationbased cohort study with 14 years of followup. Lancet 1987;1:59-62.
51. Leifsson BG, Ahren B: Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996; 81: 2149-2153.
52. Lind L, et al: Serum calcium: A new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997; 50: 967-973.
53. Larsson SC, et al: Magnesium, calcium, potassium, and sodium intakes and risk of stroke in male smokers. Arch Intern Med 2008; 168: 459-465.
54. Carlson LA, et al: Effects of oral calcium upon serum cholesterol and triglycerides in patients with hyperlipidemia. Atherosclerosis 1971; 14: 391-400.
55. Karanja N, et al: Plasma lipids and hypertension: Response to calcium supplementation. Am J Clin Nutr 1987; 45: 60-65.
56. De Bacquer D, et al: Epidemiological evidence for an association between serum calcium and serum lipids. Atherosclerosis 1994; 108: 193-200.
57. Reid IR, et al: Effects of calcium supplementation on serum lipid concentrations in normal older women: A randomized controlled trial. Am J Med 2002; 112: 343-347.
58. Wareham NJ, et al: Glucose intolerance is associated with altered calcium homeostasis: A possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997; 46: 1171-1177.
59. Sun G, et al: Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and-cell function in the Newfoundland population. Diabetes 2005; 54: 3336-3339.
60. Renaud S, et al: Platelet functions in relation to diet and serum lipids in British farmers. Br Heart J 1981; 46: 562-570.
61. Renaud S, et al: Nutrients, platelet function and composition in nine groups of French and British farmers. Atherosclerosis 1986; 60: 37-48.
62. Larsson TE, et al: Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010; 30: 333-339.
63. Tonelli M, et al: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
64. Detrano R, et al: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-1345.
65. Weintraub WS, Diamond GA: Predicting cardiovascular events with coronary calcium scoring. N Engl J Med 2008; 358: 1394-1396.
66. Manson JE, et al: Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause 2010; 17: 683-691.
67. Reid IR, Bolland MJ, Grey A: Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) 2010; 73: 689-695.
68. Ascherio A, et al: Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998; 98: 1198-1204.
69. Iso H, et al: Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. Stroke 1999; 30: 1772-1779.
70. Ross RK, et al: Prospective evaluation of dietary and other predictors of fatal stroke in Shanghai, China. Circulation 1997; 96: 50-55.
71. Weng LC, et al: Is ischemic stroke risk related to folate status or other nutrients correlated with folate intake? Stroke 2008; 39: 3152-3158.
72. Ovbiagele B, et al: Are elevated admission calcium levels associated with better outcomes after ischemic stroke? Neurology 2006; 67: 170-173.
73. Ovbiagele B, et al: Serum calcium as prognosticator in ischemic stroke. Stroke 2008; 39: 2231-2236.
74. Peuler JD, Schelper RL: Partial protection from salt-induced stroke and mortality by high oral calcium in hypertensive rats. Stroke 1992; 23: 532-538.
75. Pfeifer M, et al: Effects of a short-term vitamin D 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-1637.
76. Nagpal J, Pande JN, Bhartia A: A doubleblind, randomized, placebo-controlled trial of the short-term effect of vitamin D 3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009; 26: 19-27.
77. Scragg R, Khaw KT, Murphy S: Effect of winter oral vitamin D 3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995; 49: 640-646.
78. Krause R, et al: Ultraviolet B and blood pressure. Lancet 1998; 352: 709-710.
79. Joffres MR, Reed DM, Yano K: Relationship of magnesium intake and other dietary factors to blood pressure: The Honolulu heart study. Am J Clin Nutr 1987; 45: 469-475.
80. Sowers MR, Wallace RB, Lemke JH: The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr 1985; 42: 135-142.
81. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-719.
82. Hypponen E, et al: 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298-305.
83. Hintzpeter B, et al: Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008; 62: 1079-1089.
84. Snijder MB, et al: Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women. J Intern Med 2007; 261: 558-565.
85. Scragg R, et al: Plasma 25-hydroxyvitamin D 3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 1992; 2: 697-703.
86. Scragg R, Khaw KT, Murphy S: Lifestyle factors associated with winter serum 25-hydroxyvitamin D levels in elderly adults. Age Ageing 1995; 24: 271-275.
87. Lind L, et al: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
88. Scragg R, et al: Serum 25-hydroxycholecalciferol concentration in newly detected hypertension. Am J Hypertens 1995; 8: 429-432.
89. Rueda S, et al: Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes Surg 2008; 18: 151-154.
90. Reis JP, et al: Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-1555.
91. Argiles A: Blood pressure is correlated with vitamin D 3 serum levels in dialysis patients. Blood Purif 2002; 20: 370-375.
92. Brickmann AS, et al: Calcitropic hormones, platelet calcium, and blood pressure in essential hypertension. Hypertension 1990; 16: 515-522.
93. Kokot F, et al: Influence of ultraviolet irradiation on plasma vitamin D and calcitonin levels in humans. Kidney Int Suppl 1989; 27:S143-S146.
94. Muray S, et al: Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J. Hypertens 2003; 21: 2069-2075.
95. Forouhi NG, et al: Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-2625.
96. Forman JP, et al: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-1069.
97. Forman JP, Curhan GC, Taylor EN: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008; 52: 828-832.
98. Jorde R, et al: Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 2010; 55: 792-798.
99. Jorde R, Svartberg J, Sundsfjord J: Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 2005; 23: 1639-1644.
100. Xiang W, et al: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288:E125-E132.
101. Kong J, et al: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008; 74: 1577-1581.
102. Bonizzi G, Karin M: The two NF-B activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288.
103. Guijarro C, Egido J: Transcription factor-B (NF-B) and renal disease. Kidney Int 2001; 59: 415-424.
104. Pilz S, et al: Vitamin D status and arterial hypertension: A systematic review. Nat Rev Cardiol 2009; 6: 621-630.
105. Wong MS, et al: Vitamin D derivatives acutely reduce endothelium- dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008; 295:H289-H296.
106. Talmor Y, et al: Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294:F1059-F1064.
107. Richart T, Li Y, Staessen JA: Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens 2007; 20: 1007-1015.
108. Grimes DS, Hindle E, Dyer T: Sunlight, cholesterol and coronary heart disease. QJM 1996; 89: 579-589.
109. Douglas AS, et al: Seasonal variation in coronary heart disease in Scotland. J Epidemiol Community Health 1995; 49: 575-582.
110. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double-blind controlled trial. BMJ 2003; 326: 469.
111. LaCroix AZ, et al: Calcium plus vitamin D supplementation and mortality in postmenopausal women: The Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009; 64: 559-567.
112. Wang TJ, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
113. Dobnig H, et al: Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with allcause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349.
114. Kendrick J, et al: 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. Atherosclerosis 2009;205:255-260.
115. Melamed ML, et al: 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
116. Kim DH, et al: Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102: 1540-1544.
117. Rajasree S, et al: Serum 25-hydroxyvitamin D 3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol 2001; 17: 567-571.
118. Scragg R, et al: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D 3 levels: A communitybased study. Int J Epidemiol 1990; 19: 559-563.
119. Giovannucci E, et al: 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008; 168: 1174-1180.
120. Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483-492.
121. Rashid G, et al: Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 2008; 38: 798-803.
122. Judd SE, Tangpricha V: Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009; 338: 40-44.
123. O'Connell TD, et al: 1,25-Dihydroxyvitamin D 3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272:H1751-H1758.
124. Watson KE, et al: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-1760.
125. Penckofer S, et al: Vitamin D and diabetes: Let the sunshine in. Diabetes Educ 2008; 34: 939-940, 942, 944 passim.
126. Pittas AG, et al: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017-2029.
127. Poole KE, et al: Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-245.
128. Pilz S, et al: Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39: 2611-2613.
129. Teng M, et al: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
130. Teng M, et al: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
131. Kalantar-Zadeh K, et al: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
132. Tentori F, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
133. Palmer SC, et al: Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
134. Agarwal R, et al: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
135. Alborzi P, et al: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
136. Fishbane S, et al: Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am J Kidney Dis 2009; 54: 647-652.
137. Melamed ML, et al: 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
138. Zittermann A, et al: Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112.
139. Cooper R, et al: Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102: 3137-3147.
140. Pearce N: Commentary: The rise and rise of corporate epidemiology and the narrowing of epidemiology's vision. Int J Epidemiol 2007; 36: 713-717.